Vertex Pharmaceuticals Announces New England Journal of Medicine Publishes Data From Two Phase 3 Studies of INCIVEK in Hepatitis C

Vertex Pharmaceuticals Incorporated VRTX today announced that the New England Journal of Medicine published data from two Phase 3 studies of INCIVEK tablets, which showed that INCIVEK combination therapy significantly improved rates of sustained viral response in a broad group of people with genotype 1 chronic hepatitis C who were new to treatment and those who were treated previously but not cured. Data from these studies, which included nearly 2,000 people, are published in the June 23, 2011 issue of NEJM.